Key result
Temporary post-bevacizumab SBP drop >=20 mm Hg is linked to ~47% lower treatment failure risk.
Why the study?
Does a temporary blood pressure drop after bevacizumab administration predict time-to-treatment failure in advanced colorectal cancer patients?
Cohort (n=81)
No
Does a temporary blood pressure drop after bevacizumab administration predict time-to-treatment failure in advanced colorectal cancer patients?
Hazard Ratio: 0.53 (95% CI 0.31–0.89)
Absolute Event Rate: 291% vs 162%
p-value: p=0.02
A temporary blood pressure drop after bevacizumab administration may serve as a predictive marker for treatment efficacy in advanced colorectal cancer.
May warrant BP monitoring during bevacizumab; leaves open prognostic relevance in advanced colorectal cancer.
BACKGROUND: A blood pressure drop after bevacizumab administration and its clinical significance have not been previously reported. METHODS: Blood pressure data at 0, 90, and 180 min after a total of 162 bevacizumab administrations in 81 advanced colorectal cancer patients were retrospectively investigated. RESULTS: Twenty-five patients (30%) demonstrated an average temporary drop of 20 mm Hg or more in systolic blood pressure. We classified these 25 patients as group A and the others as group B. Median time-to-treatment failure (TTF) was significantly longer in group A than in group B (291 vs 162 days; P=0.02). Furthermore, the proportion of patients who required intervention with antihypertensive drugs during bevacizumab treatment was significantly higher in group A than in group B (36% vs 4%; P<0.01). CONCLUSION: This study suggests that a temporary blood pressure drop after bevacizumab administration could be a predictive marker for bevacizumab treatment.
No takes yet. Share an insight, caveat, or question.
Kanai et al. (2011) conducted a cohort in Advanced colorectal cancer (n=81). Temporary systolic blood pressure drop ≥20 mm Hg after bevacizumab administration vs. No temporary blood pressure drop ≥20 mm Hg was evaluated on Time-to-treatment failure (TTF) in days (HR 0.53, 95% CI 0.31-0.89, p=0.02). A temporary systolic blood pressure drop of 20 mm Hg or more after bevacizumab administration was associated with a significantly longer median time-to-treatment failure (291 vs 162 days; HR 0.53).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: